Afeyan Noubar
- SEC CIK
- 0001222012
In the past year, 1 open-market purchase filing worth $75.0M and 2 sale filings worth $1.14M.
Current role at each company
- MRNA Moderna, Inc.Directoras of May 22, 2026
- GENB Generate Biomedicines, Inc.Director, 10% Owneras of Mar 2, 2026
- FHTX Foghorn Therapeutics Inc.Director, 10% Owneras of Jan 15, 2026
- SANA Sana Biotechnology, Inc.10% Owneras of Feb 14, 2024
- SGTX Sigilon Therapeutics, Inc.10% Owneras of Aug 15, 2023
Show 6 more companies
- EVLO Evelo Biosciences, Inc.10% Owneras of Jul 13, 2023
- OMGA Omega Therapeutics, Inc.Director, 10% Owneras of Jun 9, 2023
- AXLA Axcella Health Inc.10% Owneras of Oct 17, 2022
- CDAK Codiak BioSciences, Inc.10% Owneras of Sep 16, 2022
- MCRB Seres Therapeutics, Inc.10% Owneras of Jul 7, 2022
- RUBY Rubius Therapeutics, Inc.Director, 10% Owneras of May 13, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- $75.0M
- 1 filing
- Sold
- $1.14M
- 2 filings
- Net
- +$73.9M
- Bought minus sold
- Companies
- 2
- With open-market trades
Trades
Every Form 4 that lists Afeyan Noubar as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
MRNA Moderna, Inc.
Director85 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 22, 2026 (view filing) | May 21 | 1 day | Afeyan NoubarDirector | SSale | −9.26K | $46.84 | −$433.9K | −70.2%3.92K after | |
| Dec 15, 2025 (view filing) | Dec 11 | 4 days | Afeyan NoubarDirector | SSale | −23.9K | $29.49 | −$703.4K | −85.9%3.92K after | |
| Aug 2, 2024 (view filing) | Jul 31 | 2 days | Afeyan NoubarDirector | SSale | −15.0K | $119.96 | −$1.80M | −0.7%2.22M after | 4 lots10b5-1 |
| Jul 26, 2024 (view filing) | Jul 24 | 2 days | Afeyan NoubarDirector | SSale | −15.0K | $117.80 | −$1.77M | −0.7%2.24M after | 4 lots10b5-1 |
| Jul 19, 2024 (view filing) | Jul 17 | 2 days | Afeyan NoubarDirector | SSale | −15.0K | $122.84 | −$1.84M | −0.7%2.25M after | 5 lots10b5-1 |
| Jul 12, 2024 (view filing) | Jul 10 | 2 days | Afeyan NoubarDirector | SSale | −15.0K | $117.08 | −$1.76M | −0.7%2.27M after | 5 lots10b5-1 |
| Jun 28, 2024 (view filing) | Jun 26 | 2 days | Afeyan NoubarDirector | SSale | −15.0K | $127.22 | −$1.91M | −0.7%2.28M after | 10 lots10b5-1 |
| Jun 21, 2024 (view filing) | Jun 18 | 3 days | Afeyan NoubarDirector | SSale | −15.0K | $133.57 | −$2.00M | −0.6%2.30M after | 5 lots10b5-1 |
| Jun 14, 2024 (view filing) | Jun 12 | 2 days | Afeyan NoubarDirector | SSale | −15.0K | $147.20 | −$2.21M | −0.6%2.31M after | 8 lots10b5-1 |
| Jun 11, 2024 (view filing) | Jun 11 | Same day | Afeyan NoubarDirector | SSale | −202.8K | $148.33 | −$30.1M | −11.7%1.53M after | 4 lots |
GENB Generate Biomedicines, Inc.
Director, 10% Owner2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 2, 2026 (view filing)5:52 PM ET | Mar 2 | Same day | Afeyan Noubar and 7 othersDirector, 10% Owner | PPurchase | +4.69M | $16.00 | +$75.0M | New position1.56M after | 3 lotsDuplicate filing |
| Mar 2, 2026 (view filing)5:42 PM ET | Mar 2 | Same day | Afeyan Noubar and 6 othersDirector, 10% Owner | PPurchase | +4.69M | $16.00 | +$75.0M | New position1.56M after | 3 lots |
FHTX Foghorn Therapeutics Inc.
Director, 10% Owner1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 24, 2024 (view filing)5:05 PM ET | May 22 | 2 days | Afeyan Noubar and 3 others10% Owner | PPurchase | +3.63M | $5.51 | +$20.0M | –1.81M after | Derivative2 lots |
SANA Sana Biotechnology, Inc.
10% Owner3 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 14, 2024 (view filing)4:00 PM ET | Feb 12 | 2 days | Afeyan Noubar and 1 other10% Owner | PPurchase | +2.73M | $5.50 | +$15.0M | –2.73M after | Derivative |
| Jun 8, 2023 (view filing)7:00 PM ET | Jun 6-7 | 2 days | Afeyan Noubar and 3 others10% Owner | SSale | −403.8K | $6.27 | −$2.53M | −22.6%1.38M after | 4 lots |
| May 26, 2023 (view filing)8:00 PM ET | May 24-26 | 2 days | Afeyan Noubar and 3 others10% Owner | SSale | −545.2K | $6.47 | −$3.53M | −27.7%1.43M after | 6 lots |
EVLO Evelo Biosciences, Inc.
10% Owner2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 13, 2023 (view filing)5:15 PM ET | Jul 11 | 2 days | Afeyan Noubar and 7 others10% Owner | PPurchase | +5.41M | $2.31 | +$12.5M | New position3.93M after | 3 lots |
| Jun 1, 2022 (view filing)7:00 PM ET | May 27 | 5 days | Afeyan Noubar and 8 others10% Owner | PPurchase | +27.4M | $1.46 | +$40.0M | New position13.7M after | 5 lots |
OMGA Omega Therapeutics, Inc.
Director, 10% Owner2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 27, 2023 (view filing)5:20 PM ET | Feb 27 | Same day | Afeyan Noubar and 3 othersDirector, 10% Owner | PPurchase | +3.32M | $5.78 | +$19.2M | New position1.33M after | 2 lots |
| Aug 5, 2021 (view filing)5:41 PM ET | Aug 3 | 2 days | Afeyan Noubar and 9 othersDirector, 10% Owner | PPurchase | +1.18M | $17.00 | +$20.0M | +266.7%1.62M after | 3 lots |
AXLA Axcella Health Inc.
10% Owner2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 17, 2022 (view filing)4:42 PM ET | Oct 13 | 4 days | Afeyan Noubar and 4 others10% Owner | PPurchase | +10.4M | $1.64 | +$17.0M | New position3.05M after | 5 lots |
| Mar 18, 2022 (view filing)8:30 AM ET | Mar 16 | 2 days | Afeyan Noubar and 5 others10% Owner | PPurchase | +6.32M | $1.91 | +$12.1M | New position4.47M after | 3 lots |
CDAK Codiak BioSciences, Inc.
10% Owner2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 16, 2022 (view filing)7:30 PM ET | Sep 15 | 1 day | Afeyan Noubar and 3 others10% Owner | PPurchase | +933.3K | – | – | +365.2%1.19M after | 2 lots |
| Sep 16, 2022 (view filing)7:30 PM ET | Sep 15 | 1 day | Afeyan Noubar and 3 others10% Owner | PPurchase | +933.3K | – | – | –210.7K after | Derivative2 lots |
MCRB Seres Therapeutics, Inc.
10% Owner1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 7, 2022 (view filing)5:00 PM ET | Jul 5 | 2 days | Afeyan Noubar and 3 others10% Owner | PPurchase | +8.74M | $3.15 | +$27.5M | New position5.83M after | 2 lots |